Telix Ebit vs Selling And Marketing Expenses Analysis
TLX Stock | 24.62 0.12 0.49% |
Telix Pharmaceuticals financial indicator trend analysis is much more than just breaking down Telix Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Telix Pharmaceuticals is a good investment. Please check the relationship between Telix Pharmaceuticals Ebit and its Selling And Marketing Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Ebit vs Selling And Marketing Expenses
Ebit vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Telix Pharmaceuticals Ebit account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have very week relationship.
The correlation between Telix Pharmaceuticals' Ebit and Selling And Marketing Expenses is 0.24. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of Telix Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Telix Pharmaceuticals' Ebit and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Telix Pharmaceuticals are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Ebit i.e., Telix Pharmaceuticals' Ebit and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | 0.24 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Ebit
Selling And Marketing Expenses
Most indicators from Telix Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Telix Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Selling General Administrative is likely to gain to about 82.9 M in 2024, despite the fact that Tax Provision is likely to grow to (2 M).
Telix Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Telix Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Telix Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 233.4M | 257.3M | 282.2M | 310.6M | 323.7M | 221.8M | |
Total Assets | 102.6M | 164.4M | 109.8M | 260.6M | 398.3M | 418.2M | |
Total Current Liabilities | 10.6M | 20.0M | 38.0M | 85.6M | 157.4M | 165.3M | |
Total Stockholder Equity | 70.1M | 79.0M | 2.2M | 80.0M | 148.9M | 156.4M | |
Property Plant And Equipment Net | 1.9M | 4.8M | 6.3M | 18.8M | 30.5M | 32.0M | |
Net Debt | (42.5M) | (75.7M) | (19.5M) | (105.9M) | (105.8M) | (100.5M) | |
Retained Earnings | (48.1M) | (93.0M) | (173.5M) | (272.8M) | (263.7M) | (250.5M) | |
Accounts Payable | 7.0M | 5.8M | 11.9M | 16.8M | 32.8M | 34.5M | |
Cash | 44.6M | 77.9M | 22.0M | 116.3M | 123.2M | 63.5M | |
Non Current Assets Total | 43.9M | 70.8M | 62.3M | 87.4M | 173.5M | 182.1M | |
Cash And Short Term Investments | 44.6M | 77.9M | 22.0M | 116.3M | 123.2M | 63.5M | |
Net Receivables | 13.0M | 14.2M | 20.8M | 39.4M | 64.8M | 68.0M | |
Liabilities And Stockholders Equity | 102.6M | 164.4M | 109.8M | 260.6M | 398.3M | 418.2M | |
Non Current Liabilities Total | 21.3M | 64.5M | 68.2M | 92.9M | 92.0M | 48.8M | |
Total Liab | 31.9M | 84.4M | 106.2M | 178.4M | 249.4M | 261.9M | |
Property Plant And Equipment Gross | 1.9M | 4.8M | 8.4M | 22.2M | 36.3M | 38.1M | |
Total Current Assets | 58.7M | 93.6M | 47.5M | 173.2M | 224.8M | 236.1M | |
Common Stock | 115.9M | 167.1M | 170.8M | 371.0M | 446.3M | 468.6M | |
Short Long Term Debt Total | 2.1M | 2.2M | 2.5M | 10.4M | 17.4M | 18.3M | |
Other Current Liab | 3.2M | 10.1M | 19.3M | 55.8M | 100.5M | 105.5M | |
Other Liab | 20.3M | 57.4M | 67.8M | 80.0M | 92.0M | 96.6M | |
Net Tangible Assets | 28.1M | 19.8M | (53.6M) | 21.0M | 18.9M | 10.2M | |
Non Currrent Assets Other | (4.1M) | 183K | (3.9M) | 327K | 586K | 615.3K | |
Other Assets | 82K | 183K | 212K | 4.0M | 4.6M | 4.8M | |
Long Term Debt Total | 1.6M | 1.4M | 1.9M | 9.8M | 11.3M | 11.8M | |
Inventory | 542K | 633K | 3.5M | 8.5M | 17.3M | 18.2M | |
Other Current Assets | 530K | 859K | 1.2M | 9.1M | 19.5M | 20.5M | |
Other Stockholder Equity | 2.2M | 4.9M | 4.8M | (562K) | (1.0) | (0.95) | |
Net Invested Capital | 70.8M | 79.4M | 2.2M | 83.3M | 158.1M | 166.0M | |
Short Long Term Debt | 469K | 264K | 19K | 964K | 867.6K | 911.0K | |
Accumulated Other Comprehensive Income | 2.2M | 4.9M | 4.8M | (18.2M) | (33.7M) | (32.0M) | |
Net Working Capital | 48.1M | 73.7M | 9.6M | 87.7M | 67.4M | 56.9M | |
Short Term Debt | 490K | 767K | 632K | 641K | 1.6M | 874.9K | |
Intangible Assets | 41.9M | 59.2M | 55.7M | 59.0M | 104.8M | 56.3M | |
Property Plant Equipment | 1.9M | 4.8M | 6.3M | 18.8M | 21.7M | 22.7M | |
Long Term Debt | 292K | 95K | 0.0 | 3.3M | 8.2M | 8.6M | |
Capital Stock | 115.9M | 167.1M | 170.8M | 371.0M | 446.3M | 246.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.